Sebela Women's Health Inc, part of US pharmaceutical company Sebela Pharmaceuticals, announced on Wednesday that its MIUDELLA Hormone-Free Copper Intrauterine System (IUS) has been named to TIME's list of the best inventions of 2025.
Sebela says that MIUDELLA is the first hormone-free copper intrauterine device (IUD) in the US in over 40 years. It was approved by the US Food and Drug Administration in February 2025 for the prevention of pregnancy in females of reproductive potential for up to three years, and it is expected to be available to patients through trained healthcare providers in the US in the first half of 2026.
To compile this year's list, TIME solicited nominations from TIME editors and correspondents around the world through an online application process, paying special attention to growing fields -- such as health care and AI. It then evaluated each contender on several key factors, including originality, efficacy, ambition, and impact.
Sebela's MIUDELLA Hormone-Free Copper IUS recognised in TIME's best inventions of 2025
Merck reports positive Phase 3 data for investigational two-drug HIV regimen doravirine/islatravir
60 Degrees reports first patient has tested negative for babesiosis in tafenoquine study
Minovia Therapeutics' MNV-201 receives FDA Orphan Drug Designation for Myelodysplastic Syndrome
BeOne Medicines' sonrotoclax receives FDA Breakthrough Therapy Designation for MCL
Ascletis selects once-monthly SQ GLP-1R/GIPR dual peptide agonist, ASC35, for clinical development
Celltrion's biosimilar EYDENZELT (aflibercept-boav) approved by US FDA
Rigel Pharmaceuticals begins dose expansion phase of R289 study in lower-risk MDS
Precision NeuroMed's glioblastoma multiforme treatment granted FDA Orphan Drug Designation
Merck completes acquisition of Verona Pharma to expand cardio-pulmonary portfolio